Bridging Borders to Fight a Critical Superbug Threat

WALTHAM, MA – June 16, 2026 – In the quiet, persistent war against antimicrobial resistance (AMR), a new strategic alliance marks a significant step forward. Innoviva Specialty Therapeutics has announced an exclusive licensing agreement with global pharmaceutical giant Dr. Reddy’s Laboratories to bring XACDURO®, a novel antibiotic, to parts of the world desperate for new weapons against one of the most dangerous superbugs. The deal grants Dr. Reddy’s the rights to develop and commercialize the drug in South and Central America, the Caribbean, Russia, and the Commonwealth of Independent States (CIS) countries—regions where the threat is particularly acute.

This isn't just another pharmaceutical transaction. It's a calculated move to deploy a highly specialized treatment where it's needed most, targeting a pathogen the World Health Organization (WHO) has classified as a "critical threat." The agreement underscores a shift in strategy for tackling AMR: combining cutting-edge drug development with the on-the-ground expertise of regional powerhouses to bypass logistical hurdles and accelerate patient access. For Innoviva, it’s a way to expand the global reach of its critical care portfolio; for millions of patients, it could mean a second chance.

A Targeted Weapon for a Deadly Foe

At the heart of this partnership is Acinetobacter baumannii, a formidable bacterium responsible for severe hospital-acquired and ventilator-associated pneumonia (HABP/VABP). Thriving in intensive care units, this pathogen preys on the most vulnerable patients. What makes it so dangerous is its remarkable ability to develop resistance to many, and sometimes all, available antibiotics, particularly a class of last-resort drugs called carbapenems. The WHO's 2024 Bacterial Priority Pathogens List places carbapenem-resistant Acinetobacter baumannii (CRAB) in its highest "critical priority" category, signaling an urgent need for new therapies.

XACDURO®, which gained FDA approval in May 2023, is the first and only antibiotic specifically indicated for HABP/VABP caused by susceptible strains of Acinetobacter. It combines sulbactam, an older antibiotic that has intrinsic activity against Acinetobacter, with durlobactam, a novel beta-lactamase inhibitor. This inhibitor acts as a bodyguard, protecting sulbactam from the defensive enzymes the bacteria produce, allowing it to effectively kill the pathogen.

Clinical data from the Phase 3 ATTACK trial highlights its tangible difference. The drug proved non-inferior to colistin, another last-line antibiotic often used for these infections, in preventing death. However, XACDURO® demonstrated a significant advantage in clinical cure rates and, crucially, a more favorable safety profile. This is a critical distinction, as colistin is known for its high risk of kidney damage, a severe complication in already critically ill patients. By offering a potentially safer and effective alternative, XACDURO® represents a major therapeutic advance.

The Power of a Strategic Partnership

Innoviva's decision to partner with Dr. Reddy's is a masterclass in strategic execution. Bringing a specialized intravenous drug to diverse and complex markets like Latin America and the CIS countries is a monumental task, fraught with unique regulatory, logistical, and commercial challenges. Rather than building this infrastructure from scratch, Innoviva is leveraging the established might of a partner with deep regional roots.

Dr. Reddy’s Laboratories is not just a distributor; it is a global pharmaceutical company with a market capitalization exceeding $11 billion and a proven track record in both manufacturing and commercializing complex medicines worldwide. The Indian-based firm has a strong presence in emerging markets and extensive experience navigating the intricate regulatory pathways of agencies like Brazil's ANVISA. Under the agreement, Dr. Reddy's assumes full responsibility for all development, regulatory filings, and commercialization activities in the licensed territories.

"This agreement reflects our ongoing commitment to addressing antimicrobial resistance by expanding access to important therapeutics for patients and healthcare systems facing serious, difficult-to-treat infections," said Patricia Drake, Chief Commercial Officer of Innoviva Specialty Therapeutics, in the company's announcement. "Dr. Reddy’s brings strong regional capabilities and experience in infectious disease treatments, and we believe this partnership provides a practical path to broaden XACDURO’s global reach while maintaining our focus on disciplined execution." This model of collaboration allows Innoviva to de-risk its international expansion while ensuring its life-saving therapy can reach patients efficiently.

Fueling Growth While Meeting Unmet Needs

For Innoviva, this licensing deal is more than a public health victory; it is a financially astute move that aligns perfectly with its growth strategy. The agreement secures an upfront payment and promises future revenue through regulatory and commercial milestone payments, plus tiered royalties on net sales. This structure provides Innoviva with non-dilutive capital and a long-term revenue stream, diversifying its income beyond its existing product portfolio and royalty streams.

With a strong balance sheet showing more cash than debt and impressive gross profit margins, Innoviva is well-positioned to execute such strategic initiatives. By outsourcing the heavy lifting of commercialization in these territories, the company can focus its resources on its core markets and the continued development of its pipeline. Analysts see significant upside potential for the company, and deals like this reinforce confidence in management's ability to unlock value from its assets.

The true impact, however, is measured in the regions set to benefit. In some parts of Latin America and the CIS, the prevalence of carbapenem-resistant Acinetobacter in hospitals reportedly exceeds 70%. For clinicians in these areas, treatment options are dwindling, and mortality rates for these infections are alarmingly high. The introduction of a new, effective, and safer antibiotic is not a marginal improvement—it is a paradigm shift. This partnership bridges the gap between American innovation and global need, creating a sustainable model where commercial success and positive public health outcomes are intrinsically linked. The path to getting XACDURO® approved and into hospitals across these new territories will require time and expertise, but the journey has now officially begun.